Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations ...

TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...

KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, has discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs.

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer ...

Sydney, Australia Monday, March 16, 2026, 10:00 Hrs [IST] ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

An ASX biotech formerly worth over $500 million has lost most of its value after its drug failed to treat lung cancer ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.